BioNTech SE (BNTX) Liabilities and Shareholders Equity (2018 - 2025)

BioNTech SE has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $25.6 billion for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $25.6 billion, up 6.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $97.3 billion (up 0.53% YoY), and the FY2025 annual result was $24.8 billion, up 3.19% from the prior year.
• Liabilities and Shareholders Equity came in at $25.6 billion for Q4 2025 at BioNTech SE, up from $24.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $25.6 billion in Q4 2025 to a low of $5.1 billion in Q1 2021.
• The 5-year median for Liabilities and Shareholders Equity is $23.8 billion (2022), against an average of $21.7 billion.
• Across the five-year window, Liabilities and Shareholders Equity surged 927.56% in 2021 and dropped 7.85% in 2025, its largest moves.
• BioNTech SE's Liabilities and Shareholders Equity stood at $18.1 billion in 2021, then surged by 31.15% to $23.8 billion in 2022, then advanced by 4.22% to $24.8 billion in 2023, then retreated by 2.74% to $24.1 billion in 2024, then advanced by 6.32% to $25.6 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $25.6 billion (Q4 2025), $24.9 billion (Q3 2025), and $24.5 billion (Q2 2025), per Business Quant data.